BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma (HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because most tumors acquire drug resistance over time. As the PI3K/AKT/mTOR signaling pathway is also activated abnormally in HCC,...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Transl Res
Autori principali: Li, Amin, Zhang, Rongbo, Zhang, Yinci, Liu, Xueke, Wang, Ruikai, Liu, Jiachang, Liu, Xinkuang, Xie, Yinghai, Cao, Weiya, Xu, Ruyue, Ma, Yongfang, Cai, Wenpeng, Wu, Binquan, Cai, Shuyu, Tang, Xiaolong
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6789287/
https://ncbi.nlm.nih.gov/pubmed/31632530
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi